TP53 and cancer: Genetic alteration of p53 disrupts cancer cell secretion of pro-inflammatory cytokines (Bezzi et al., 2018; Wellenstein et al., 2019; Blagih et al., 2020b) and enhancement of antigen presentation (Zhu et al., 1999; Wang et al., 2013), but mutant p53 can also enhance the generation of neoantigens (Chasov et al., 2021) that supports response to ICI.